InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [3] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor C5aR [3] - InflaRx's lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody that has shown disease-modifying clinical activity in various studies [3] Financial and Operational Updates - InflaRx plans to publish its financial and operating results for Q4 and full year 2024 on March 20, 2025, with no conference call scheduled [1] - The company will participate in two upcoming investor conferences, including the Leerink Global Healthcare Conference from March 9-12, 2025, and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025 [1][2] Product Development - InflaRx is also developing INF904, an orally administered small molecule inhibitor of the C5a receptor [3] - The company was founded in 2007 and has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [3][4]